Centessa Pharmaceuticals PLC 8-K filings

Centessa Pharmaceuticals has been acquired by Eli Lilly and Company in a transaction valued at $38.00 per share plus contingent value rights.

Centessa Pharmaceuticals announced the expiration of the HSR Act waiting period, marking a key milestone in its acquisition by Eli Lilly.

Eli Lilly and Company will acquire Centessa Pharmaceuticals plc for an upfront cash payment of $38.00 per share, with additional contingent value rights totaling up to $9.00 per share.

Centessa Pharmaceuticals PLC has finalized separation and advisory terms with former CEO Saurabh Saha, including equity vesting, a target bonus, and an advisory role.

Centessa Pharmaceuticals plc has filed an amendment detailing the employment agreement for its new Chief Executive Officer, Dr. Mario Alberto Accardi, effective January 1, 2026.

Centessa Pharmaceuticals announces a strategic leadership transition, appointing Dr. Mario Alberto Accardi as CEO to advance its pure-play orexin portfolio into multiple neuroscience indications.

Centessa Pharmaceuticals plc has entered into an amended sales agreement with Leerink Partners LLC to potentially sell up to $250 million in American Depositary Shares through an at-the-market offering.

Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares at $21.50 per ADS, expecting gross proceeds of $250 million.

Centessa Pharmaceuticals announced its Q3 2025 financial results and positive Phase 2a data for its lead Orexin Receptor 2 (OX2R) agonist, ORX750, for narcolepsy and idiopathic hypersomnia.

Centessa Pharmaceuticals reported Q2 2025 financial results and highlighted significant progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts anticipated this year.

Centessa Pharmaceuticals PLC announced that all resolutions, including the re-appointment of directors and authorization for share allotment, were approved by shareholders at its 2025 Annual General Meeting held on June 20, 2025.

Centessa Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ORX142, a novel orexin receptor 2 (OX2R) agonist, enabling the initiation of a Phase 1 clinical study.

Centessa Pharmaceuticals PLC announced the appointment of Raphael Deferiere, a seasoned Certified Public Accountant and former Ernst & Young Assurance Partner, as its new Chief Accounting Officer, effective May 27, 2025.

Centessa Pharmaceuticals announced its Q1 2025 financial results, highlighting progress in its orexin receptor 2 (OX2R) agonist pipeline, including the ORX750 Phase 2a CRYSTAL-1 study.

Centessa Pharmaceuticals reports progress in its orexin receptor 2 (OX2R) agonist program and financial results for the fourth quarter and full year ended December 31, 2024, with key data readouts expected in 2025.

Centessa Pharmaceuticals grants Genmab an exclusive worldwide license to its LockBody platform for research and development of new therapies, potentially yielding up to $260 million in upfront and option payments, plus milestones and royalties.

Centessa Pharmaceuticals is advancing its orexin receptor 2 (OX2R) agonist pipeline, with multiple clinical milestones expected in 2025 and a cash runway extending into mid-2027.

Centessa Pharmaceuticals has entered into a loan agreement for up to $200 million with Oxford Finance LLC, using an initial $110 million to refinance existing debt.

Centessa Pharmaceuticals announced positive interim Phase 1 data for its lead orexin agonist, ORX750, and a strategic shift to focus on its orexin program, reallocating $200 million from its discontinued SerpinPC program.

Centessa Pharmaceuticals has announced the pricing of an upsized public offering of American Depositary Shares, expected to generate approximately $225 million in gross proceeds.

Centessa Pharmaceuticals reported positive interim Phase 1 clinical data for its orexin agonist, ORX750, showing significant improvements in wakefulness and a favorable safety profile, leading to plans for Phase 2 trials.

Centessa Pharmaceuticals announced its second quarter 2024 financial results and provided updates on its clinical programs, including the initiation of a Phase 1 study for ORX750 and the nomination of ORX142 as a development candidate.

Centessa Pharmaceuticals successfully held its 2024 Annual General Meeting on June 25, 2024, with all proposed resolutions and director nominees being approved by shareholders.

Centessa Pharmaceuticals has appointed John Crowley as Chief Financial Officer and Gregory Weinhoff as Chief Business Officer, effective June 10, 2024.

Centessa Pharmaceuticals announced its first quarter 2024 financial results, highlighting progress in its hemophilia, narcolepsy, and oncology programs, along with a recent capital raise.

Centessa Pharmaceuticals has launched a public offering to sell 10,810,810 American Depositary Shares at $9.25 per share, aiming to raise approximately $100 million.

Centessa Pharmaceuticals has received FDA clearance to begin a Phase 1 clinical trial for ORX750, a potential treatment for narcolepsy.

Centessa Pharmaceuticals announced its fourth quarter and full-year 2023 financial results, highlighting progress in its hemophilia, orexin agonist, and LockBody technology programs.

Centessa Pharmaceuticals reported significant reductions in annualized bleed rates and target joint bleeds in patients with severe hemophilia treated with SerpinPC, with no treatment-related adverse events observed.